Imaging Neuroinflammation In COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:3 publications

Grant number: 174893

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2023
  • Known Financial Commitments (USD)

    $601,328.25
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Jeffrey H Meyer
  • Research Location

    Canada
  • Lead Research Institution

    Centre for Addiction and Mental Health/Centre de toxicomanie et de santé mentale
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

COVID-19 is infecting 1 in 100 Canadians and over 23 million people around the world. After people recover from short term breathing problems, and feelings of sickness with the virus, there can be longer term problems affecting the brain. It is believed that the virus can cause inflammation of the brain. We know that inflammation in the brain is implicated in causing depression symptoms. About 30% of those infected with COVID-19 report later elevations in level of depression and/or other symptoms of mental illness. The purpose of this study is to use state of the art brain scanning to detect whether brain inflammation is happening in those with COVID-19 who later get depression and/or other mental illnesses. There are two main purposes for this study. First, it would be the first to show definitive evidence of brain inflammation in COVID-19 with later mental illness. Second, if we discover brain inflammation, we can study treatments to see if they can prevent or remove this inflammation, using the brain scan to show that the treatment has an effect in the brain. Having a brain scan to detect COVID-19 effect in the brain is extremely important for developing new brain treatments for COVID-19: Most companies and many government funding agencies like the National Institutes of Health in the US, require use of brain scanning to show that brain treatments get into the brain as a requirement to invest funds for clinical trials.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

One-pot synthesis of cobalt-rhenium nanoparticles taking the unusual β-Mn type structure.

From Colloidal Monodisperse Nickel Nanoparticles to Well-Defined Ni/Al2O3 Model Catalysts.

Evaluation of Reoxidation Thresholds for γ-Al2O3-Supported Cobalt Catalysts under Fischer-Tropsch Synthesis Conditions.